Medicare Update from the CMS: Autologous Blood-Derived Products for Chronic Non-Healing Wounds
Decision:
CMS has determined that the evidence is adequate to conclude that autologous platelet-derived growth factor (PDGF) in a platelet poor plasma does not improve healing in chronic non-healing cutaneous wounds and, therefore, is not reasonable and necessary. CMS will continue noncoverage of this treatment.
CMS has determined, in the absence of specific evidence of benefit that there is not sufficient evidence to conclude that autologous platelet rich plasma is reasonable and necessary for the treatment of chronic non-healing cutaneous wounds. In light of the absence of data on the health outcomes of this treatment, we intend to issue a national noncoverage determination for use of this product except when used in accordance with the clinical trial policy defined in section 30-1 of the Coverage Issues Manual.
Other Information for the CMS (PDF)
